Last updated 2026-09-06
- Acquired by N2OFF Inc. for $700k, Oct 2025
- Raised $700k Seed round led by N2OFF, Inc., Oct 2025
- Raised debt round led by N2OFF, Inc., Dec 2024
Total raised
$700K
Stage
Acquired
Founded
2022
Headcount
5
HQ
Tel-Aviv-Jaffa, Israel
Sector
Drug Discovery
About
MitoCareX Bio is a computationally advanced drug discovery company specializing in the development of novel therapies for hard-to-treat cancers. The company utilizes a computationally advanced drug discovery platform, including its MITOLINE™ algorithm, to model, predict, and discover small molecules that target mitochondrial carriers (SLC25 protein family). Their innovative approach combines computational chemistry, structural biology, and precision medicine to accelerate the discovery of next-generation cancer therapeutics, with an initial focus on lung cancer and an expanded focus on pancreatic cancer. MitoCareX Bio has also expanded its research into inflammatory metabolic diseases.
Funding history · 2 rounds · $700K total
2 events/rounds · $700K Total Funding: $700K in Private Equity
Oct 2025
★ N2OFF, Inc.SciSparc Ltd.Dr. Alon SilbermanProf. Ciro Leonardo Pierri
Dec 2024
★ N2OFF, Inc.★ L.I.A. Pure Capital Ltd.
Headcount over time
5 employees (2026-09) · 1 point
Offices
Tel-Aviv-Jaffa, Israel · HQ / main office
Q&A
- What is MitoCareX Bio's primary focus?
- MitoCareX Bio is a drug discovery company focused on developing novel therapies for hard-to-treat lung cancer by targeting mitochondrial transporters (SLC25 protein family).
- When was MitoCareX Bio founded?
- MitoCareX Bio was founded in February 2022.
- What is the current status of MitoCareX Bio?
- MitoCareX Bio was acquired by N2OFF in March 2025.
- What technology does MitoCareX Bio utilize for drug discovery?
- MitoCareX Bio developed its MITOLINE algorithm and advanced computational capabilities to generate reliable 3D models for mitochondrial proteins of interest, which are then used with a cloud-based computational platform to screen small molecules.
- How many employees does MitoCareX Bio have?
- MitoCareX Bio has 1-10 employees.
- Who is the founder of MitoCareX Bio?
- Alon Silberman is the Founder & CSO of MitoCareX Bio.
- Where is MitoCareX Bio headquartered?
- MitoCareX Bio is headquartered in Tel Aviv-Yafo, Israel.
Team · 1
Alon Silberman
Founder · CEO, CSO & Founder
Sectors & technology
Primary sector
Drug Discovery
Technologies
Target customers
Business model
B2C
Tags
pharmaceuticalscancercancer-therapyoncology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | mitocarexbio.com/ |
|---|---|
| linkedin.com/company/81288396/ |
Identifiers & details
| Legal name | MitoCareX Bio Ltd. |
|---|---|
| Founded | 2022 |
| Employees (exact) | 5 |
| Status reason | Acquired by N2OFF on Mar, 2025 |
Acquisitions & public offerings
Acquired by N2OFF Inc. 2025-10 $700K
Radar intelligence
Web history (Wayback)
| Domain | mitocarexbio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516570421 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2022-02-27 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 1 |
| Registry events | 5 — other (1), people (2), charge (1), shares_capital (1) |
| Registered address | גורדון 40 גבעתיים |
Recent registry events
| Date | Event |
|---|---|
| 2025-11-12 | שינוי בתקנון |
| 2026-07-12 | עדכון דירקטורים-הוספת דירקטור |
| 2025-12-11 | רישום שעבוד |
| 2025-11-04 | העברת מניות |
| 2026-06-03 | עדכון בעלי תפקידים |